The FDA approved the ileal bile acid transporter inhibitor maralixibat (Livmarli, Mirum) for cholestatic pruritus in patients 5 years of age and older with progressive familial intrahepatic cholestasis.
Maralixibat, which is already approved for cholestatic pruritus in patients 3 months of age and older with Alagille syndrome, works to limit the reabsorption of bile acids from the terminal ileum—a process that is believed to play at least one part in the development of cholestatic pruritus